Pharma Compliance AI: How We Designed a Platform for SOP, BMR and FDA Warning Letter Review

The Short Version

A warning letter issued to another manufacturer can expose a risk that may also exist inside your own quality system. The difficult part is not reading the warning letter. The difficult part is finding which SOPs, BMRs, controls, or documentation practices inside your own company may be affected before an auditor or inspector asks the same question.

This anonymized implementation story explains how ITMTB designed and executed a limited-scale pharma compliance AI platform for that problem. The platform was not built as a generic chatbot. It was designed to compare external regulatory signals with internal controlled documents, show why a section may be affected, and support human-reviewed remediation.

The design was scalable, but the executed workload was intentionally limited in scope. That distinction matters: in regulated environments, responsible AI implementation starts with controlled boundaries, not broad automation claims.

The AI could assist review. It could not replace quality ownership, regulatory judgment, or controlled document approval.

Executive Summary

We designed a pharma compliance AI platform that could:

• Ingest FDA warning letters, CFR clauses, and approved regulatory sources.
• Read a company's SOPs, BMRs, and related controlled documents.
• Identify which internal document sections may be affected by external regulatory observations.
• Show the source evidence behind each finding.
• Suggest draft wording for impacted sections.
• Keep humans in control of final review and approval.
• Integrate with Microsoft Entra ID / Azure Active Directory for enterprise login.
• Run on AWS while respecting tenant and user access boundaries.

The important design principle was simple: the system could support first-pass review and impact assessment, but it could not become an uncontrolled approval engine.

For teams exploring AI and automation in regulated workflows, this is the line that matters most. The model is only useful if the surrounding workflow, access control, source traceability, and review process are designed properly.

Table Of Contents

1. This Was Not A Chatbot For Pharma Documents
2. Why Pharma Teams Need More Than Document Search
3. What The Platform Needed To Support
4. Why Simple RAG Was Not Enough
5. How The Review Workflow Operated
6. What A Traceable Finding Means
7. Human Review Was Built Into The Process
8. Enterprise Login And Cloud Setup
9. Architecture Decisions And Business Rationale
10. Key Implementation Risks And Safer Design Choices
11. What This Implementation Proved
12. Frequently Asked Questions

This Was Not A Chatbot For Pharma Documents

A generic chatbot can answer questions. A regulated document-review platform must show what source it used, which document version was reviewed, which section may be impacted, and who reviewed the suggested change.

That was the core product distinction. The goal was not to let a user ask broad questions like "are we compliant?" The goal was to support a structured review process:

• Which external observation triggered the concern?
• Which SOP or BMR section may be affected?
• What internal text was reviewed?
• What source evidence supports the finding?
• What should a reviewer check next?
• Was the suggested remediation accepted, rejected, or revised?

In pharma compliance, a useful answer is not enough. The system must explain where the answer came from, which document it applies to, and what a human reviewer should check.

Why Pharma Teams Need More Than Document Search

Pharma quality teams already have documents. The hard part is connecting the right external signal to the right internal procedure.

SOPs and BMRs are long, versioned, controlled, and full of operational detail. Regulatory observations may point to documentation gaps, weak controls, incomplete checks, missing responsibilities, or ambiguous acceptance criteria. Warning letters issued elsewhere can act as early signals, but manual impact assessment is slow and keyword search misses context.

The problem was not lack of documents. The problem was finding the right connection between an external regulatory observation and the company's own internal procedures.

AI without traceability is risky in this environment. The output has to be reviewable by quality and compliance teams, not merely plausible to a user reading a generated answer.

What The Platform Needed To Support

The platform was scoped around compliance-supporting workflows rather than open-ended chat.

Business need	What the platform had to support
Understand external regulatory signals	Ingest FDA warning letters and CFR clauses
Review internal controlled documents	Read SOPs, BMRs, and related documents
Find possible impact	Match external observations to internal sections
Avoid black-box answers	Show source evidence for every finding
Support remediation	Suggest draft language for impacted sections
Keep QA in control	Route suggestions for human review
Support enterprise access	Use Azure AD login
Run in the existing cloud environment	Deploy on AWS
Preserve accountability	Keep document versions, finding history, and logs

The platform was part compliance workflow, part document intelligence system, and part enterprise software build. That combination is why it fit ITMTB's work across enterprise applications, custom software development, cloud architecture, and life-sciences technology.

Why Simple RAG Was Not Enough

RAG can help retrieve information from documents. But a regulated document-review workflow needs more than retrieval and generation.

Simple document chatbot	Controlled compliance review platform
Answers questions from uploaded files	Reviews documents against regulatory sources
May retrieve similar text	Links observations to specific SOP/BMR sections
Gives a generated answer	Produces a traceable finding
May not track document version	Ties output to a document version
Useful for exploration	Designed for review workflows
Harder to audit	Built with source evidence and logs
May suggest text freely	Drafts changes for human approval

The difference is accountability. A document chatbot may help a user explore a file. A pharma compliance AI platform has to create an artifact that a reviewer can inspect, challenge, approve, or reject.

How The Review Workflow Operated

The operating model was designed to sit between regulatory intelligence and internal quality documentation. Its job was to reduce the manual burden of first-pass review while preserving human decision-making.

The workflow looked like this:

1. Regulatory documents are added. FDA warning letters, CFR clauses, and other approved regulatory sources are ingested.
2. Internal documents are added. SOPs, BMRs, and related documents are uploaded with metadata and version details.
3. Documents are broken into meaningful sections. The system identifies clauses, procedures, responsibilities, batch steps, checks, and controlled sections.
4. External observations are compared with internal content. The system looks for possible matches between warning-letter observations or CFR clauses and the company's own procedures.
5. A finding is created. A finding includes impacted document, impacted section, source reference, reason for concern, and suggested next step.
6. Remediation text is suggested where appropriate. The system may draft revised wording, but the draft remains subject to qualified human review.
7. Reviewers approve, reject, or revise. QA and compliance users remain accountable for final decisions.
8. Traceability is preserved. The platform records which version was reviewed, what source was used, and what action was taken.

The simple flow was:

External regulatory sources
-> Internal document library
-> Impact analysis
-> Traceable findings
-> Human review
-> Draft remediation
-> Controlled document update process

This is also the pattern behind mature agentic AI systems in regulated operations: the system can assist, route, draft, and record, but controlled decisions remain governed.

What A Traceable Finding Means

A traceable finding is not just an AI answer. It is a structured review item.

It says:

• Which external source triggered the concern.
• Which SOP or BMR version was checked.
• Which section may be affected.
• Why the system believes there may be a gap.
• What evidence was used.
• What action is recommended.
• Who reviewed it.
• What decision was taken.

That structure changed the risk profile of the system. Instead of asking users to trust generated text, the platform gave reviewers a review item with source evidence and workflow state.

Human Review Was Built Into The Process

The platform was designed to support quality teams, not bypass them. The AI could point to possible issues and draft possible improvements, but final judgment stayed with authorized reviewers.

That meant:

• AI suggestions were not final approvals.
• SOP and BMR changes still required qualified human review.
• Reviewers could inspect the source evidence behind a finding.
• Draft wording remained a draft until it passed the organization's controlled document process.
• Review status and decisions were tracked.

This distinction is important for buyers. A system that drafts useful language can save time. A system that quietly bypasses quality ownership creates a new compliance risk.

Enterprise Login And Cloud Setup

The users belonged to the customer's Microsoft/Azure Active Directory environment, while the application ran on AWS. This meant the platform had to respect enterprise identity policies while being deployed in a separate cloud environment.

In plain language:

• Users logged in with their enterprise account.
• Access could follow organizational roles.
• Each company's documents stayed separated.
• Internal documents were not open to all users.
• Actions and reviews could be logged.

Under The Hood

• Microsoft Entra ID / Azure AD for login.
• AWS-hosted application.
• Tenant-aware access model.
• Role-based access.
• Document-level permissions.
• Service-level logs.
• Isolated document processing pipeline.

The same architectural discipline applies broadly to life-sciences technology systems: identity, access, auditability, and data boundaries matter as much as model quality.

Architecture Decisions And Business Rationale

The technical design choices were driven by business reasons, not engineering fashion.

Technical design choice	Business reason
Separate document processing	Large SOPs and BMRs need reliable ingestion
Versioned document records	Findings must link to the exact document version
Separate regulatory source library	External references need controlled source management
Search plus AI reasoning	Keyword match alone is not enough
Structured findings	QA teams need reviewable outputs, not loose answers
Human review workflow	Compliance decisions need accountable review
Enterprise login	Users should access the system with company identity
Audit logs	The organization should know who did what and when
Cloud deployment	The platform needed scalable processing and controlled access

The system was separated into clear functional services so that document ingestion, regulatory-source management, search, findings, review workflow, identity, and audit logging could evolve without becoming one fragile application.

Area	What it handled
Identity and access	User login, roles, tenant access
Document library	SOPs, BMRs, versions, and metadata
Regulatory library	Warning letters, CFR clauses, source references
Ingestion	Document reading, section extraction, and indexing
Search and matching	Finding relevant internal and external sections
Findings	Creating structured impact items
Review workflow	Reviewer comments, decisions, and status
Rewrite support	Drafting suggested wording for human review
Audit and logs	Tracking access, errors, decisions, and changes

Technical Architecture Note

The implementation pattern can be extended with hybrid retrieval, vector search, keyword search, document-version tables, finding-run records, tenant-aware APIs, service-to-service authentication, asynchronous background jobs, and structured audit logging.

For production agent workflows that need governed execution across tools and systems, ITMTB also builds around Orchestrik, our agent orchestration platform at orchestrik.ai. In regulated settings, orchestration is valuable only when access, approvals, audit logs, and human decision points are explicit.

Key Implementation Risks And Safer Design Choices

Serious buyers trust vendors who talk about failure modes. In pharma compliance AI, the risks are not theoretical.

Risk	Why it matters	Safer design choice
AI gives a confident but wrong answer	Compliance teams may trust a weak output	Require source evidence
Finding links to the wrong document version	Review may become misleading	Store document versions
AI rewrites SOP without control	Controlled documentation process may be bypassed	Keep rewrite as draft only
Users see documents they should not see	Confidentiality and access risk	Use role-based access
External sources become outdated	Findings may rely on old references	Track source version/date
No review history	Decisions cannot be reconstructed	Maintain audit logs
One company's data mixes with another	Tenant isolation failure	Separate tenant access and storage rules

This is why regulated AI cannot be treated as a model integration exercise. The surrounding application design is where most of the safety and accountability lives.

What This Implementation Proved

This implementation showed that regulated AI systems need more than model access. They need:

• Domain-aware workflows.
• Controlled document ingestion.
• Source-backed findings.
• Version traceability.
• Human review.
• Enterprise identity integration.
• Auditability.
• Cloud deployment discipline.
• Maintainable service boundaries.

For ITMTB, the key lesson was that enterprise AI in regulated industries has to be designed around accountability first. The AI layer is useful only when the surrounding workflow, identity, access control, and review process are designed properly.

This type of platform is relevant for pharma and life-sciences organizations that need to:

• Review SOPs against regulatory expectations.
• Check BMRs for documentation gaps.
• Assess whether external warning-letter observations may apply internally.
• Create a more structured first-pass compliance review process.
• Support quality teams with evidence-linked findings.
• Improve document review without removing human approval.
• Connect AI review with enterprise identity and access controls.

When This Approach Is Not Enough

This kind of system should not be treated as a replacement for:

• QA ownership.
• Regulatory affairs judgment.
• Validation activities.
• Controlled document approval.
• Legal review.
• Inspection response strategy.
• Final GMP compliance decisions.

It can support review and remediation. It should not become an uncontrolled approval engine.

Key Takeaways

• Pharma compliance AI should support impact assessment, not replace QA or regulatory judgment.
• Traceable findings are stronger than chatbot answers because they connect source, document version, impacted section, evidence, and reviewer decision.
• Human review, enterprise login, access control, and audit logs are part of the product design, not implementation details.
• The executed workload was limited in scope, but the architecture was designed to scale across more documents, reviewers, and regulatory sources.
• The safest path is controlled first-pass review with evidence-backed suggestions and final human approval.

Need To Review Regulated Documents With AI, Without Losing Control?

ITMTB helps design and build enterprise AI systems for regulated document review, compliance workflows, and operational decision support. If your team is evaluating AI for SOP, BMR, regulatory, quality, or audit workflows, we can help map the use case, risk boundaries, architecture, and implementation path.

Request a Pharma AI Compliance Review

Frequently Asked Questions About Pharma Compliance AI Platforms

Can AI review SOPs and BMRs for pharma compliance?

AI can assist by comparing SOPs and BMRs with selected regulatory sources and highlighting possible gaps. It should not make final compliance decisions without qualified human review.

What is the difference between a document chatbot and a compliance review platform?

A document chatbot answers questions from documents. A compliance review platform creates traceable findings, links them to source evidence, tracks document versions, and supports reviewer decisions.

Can AI rewrite SOP sections?

AI can draft suggested wording for impacted SOP sections. In regulated environments, those suggestions should go through the organization's normal review and approval process before becoming controlled documentation.

Why is document versioning important?

A finding is only meaningful if it is linked to the exact version of the SOP, BMR, or regulatory source that was reviewed. Without versioning, teams may not know whether a finding still applies after a document changes.

How does enterprise login matter in this kind of system?

Enterprise login allows users to access the platform using their company identity and role structure. This helps control who can view documents, run reviews, and approve changes.

Can this kind of platform replace QA or regulatory teams?

No. It should support QA and regulatory teams by reducing first-pass review effort and improving traceability. Final interpretation, approval, and compliance accountability should remain with authorized humans.

Is this only useful for FDA-regulated companies?

No. The same architecture can support other regulated document-review workflows, but the regulatory source library, review rules, and validation expectations would change based on geography and industry.

References

• FDA warning letters - public warning-letter database used as an example of external regulatory signals.
• 21 CFR on eCFR - official Code of Federal Regulations source for FDA-related rules.
• Microsoft Entra ID documentation - enterprise identity platform used for Azure AD login patterns.
• AWS Well-Architected Framework - reference for cloud architecture, reliability, security, and operational discipline.